Cello Health (CLL)

Sector:

Health Care

Index:

FTSE AIM All-Share

 129.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 137.50
  • 52 Week Low: 96.00
  • Currency: UK Pounds
  • Shares Issued: 104.77m
  • Volume: 5,780
  • Market Cap: £135.16m
  • RiskGrade: 64

Cello Group takes over Advantage Healthcare

By Josh White

Date: Tuesday 18 Jul 2017

LONDON (ShareCast) - (ShareCast News) - Healthcare and strategic marketing group Cello Group acquired the assets of Advantage Healthcare for consideration of $1.5m cash, it announced on Tuesday.
The AIM-traded firm said further cash consideration would be paid to the vendors on a dollar-for-dollar basis to the extent that the acquired net current assets of Advantage Healthcare are more than $0.5m at the date of completion.

Additionally, deferred consideration of up to $3m would be payable in a mix of cash and shares, dependent on Advantage's financial performance over the period from 1 July 2017 to 30 June 2021

Cello said that deferred consideration would be paid in a minimum of 75% cash, with the balance in new ordinary shares.

"We are delighted to welcome Advantage Healthcare to the Cello Health family as they further support our focus in providing high value, strategic advisory services to our biopharmaceutical clients globally," said Cello Health US CEO Julia Ralston.

"We look forward to adding this team's wealth of experience, gained from both Advantage's work portfolio over the years and also senior positions held within the industry."

The board said Advantage Healthcare, founded by Debbie Glick over 20 years ago is well-established as a leading consultancy providing critical analysis and insights in biopharmaceuticals, supporting new products and business development.

Advantage is based in Princeton, New Jersey.

For the year to 31 December, Advantage Health had an unaudited turnover of $4.5m, gross profit of $3m and unadjusted operating profit of $0.3m.

As at 31 December, it had unaudited net assets of $0.4m.

Cello said the acquisition of Advantage Healthcare would complement its existing capabilities in consulting, market research, and science-based communications.

Advantage Healthcare would add "further depth" to Cello Health's ability to work from the early stages of drug development and across the life cycle to assist clients in meeting their most mission critical challenges, the board explained, which was also consistent with reinforcing Cello Health's commitment to the core US market and its overall aim of becoming a "leading" global health services company.

"Joining Cello Health will provide a win-win combination for our global healthcare clients, offering a broad base of strategic expertise and service in the pipeline and marketed products across nearly 100 disease categories," commented Advantage Healthcare CEO Debbie Glick.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

Note 2: RiskGrade figures are provided by RiskMetrics.

 

Cello Health Market Data

Currency UK Pounds
Share Price 129.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 137.50
52 Week Low 96.00
Volume 5,780
Shares Issued 104.77m
Market Cap £135.16m
RiskGrade 64

Cello Health Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
65.08% below the market average65.08% below the market average65.08% below the market average65.08% below the market average65.08% below the market average
82.86% above the sector average82.86% above the sector average82.86% above the sector average82.86% above the sector average82.86% above the sector average
Price Trend
49.02% above the market average49.02% above the market average49.02% above the market average49.02% above the market average49.02% above the market average
35.00% above the sector average35.00% above the sector average35.00% above the sector average35.00% above the sector average35.00% above the sector average
Income
8.91% above the market average8.91% above the market average8.91% above the market average8.91% above the market average8.91% above the market average
60.00% above the sector average60.00% above the sector average60.00% above the sector average60.00% above the sector average60.00% above the sector average
Growth
32.88% below the market average32.88% below the market average32.88% below the market average32.88% below the market average32.88% below the market average
41.18% below the sector average41.18% below the sector average41.18% below the sector average41.18% below the sector average41.18% below the sector average

What The Brokers Say

Strong Buy 1
Buy 0
Neutral 1
Sell 0
Strong Sell 0
Total 2
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

Cello Health Dividends

  Latest Previous
  Interim Final
Ex-Div 03-Oct-19 25-Apr-19
Paid 01-Nov-19 24-May-19
Amount 1.15p 2.75p

Trades for 15-Nov-2019

Time Volume / Share Price
13:29 1,280 @ 128.20p
11:08 4,130 @ 130.00p
10:36 370 @ 129.96p

Cello Health Key Personnel

CEO Mark Scott

Top of Page